Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 12/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 3/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | MERTK | Q12866 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2684438 | 0.91 | REN (0.40) | RENRORCKMT2ATSHR | |
| SCHEMBL2689611 | 0.90 | REN (0.42) | RENMAPTTHRBKMT2A | |
| SCHEMBL2692687 | 0.89 | REN (0.41) | RENMAPTTHRBRORCKMT2A | |
| SCHEMBL2686150 | 0.89 | REN (0.39) | RENRORCKMT2ATSHR | |
| SCHEMBL2682978 | 0.89 | REN (0.39) | RENMAPTTHRBKMT2ATSHR | |
| SCHEMBL4540202 | 0.88 | REN (0.39) | RENMAPTTHRBKMT2A | |
| SCHEMBL2685810 | 0.88 | REN (0.38) | RENRORCTSHR | |
| SCHEMBL2685474 | 0.87 | REN (0.38) | RENMAPTTHRBRORCTSHR | |
| SCHEMBL2684877 | 0.87 | REN (0.39) | RENRORCKMT2ATSHR | |
| SCHEMBL4532272 | 0.87 | REN (0.41) | RENKMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115859-A1 | 3,4,5-SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | HEROLD PETER (CH) | 2012-05-10 | — | — | US | disclosed |
| US-20090270380-A1 | 3,4,5-Substituted Piperidines as Renin Inhibitors | NOVARTIS AG (CH) | 2009-10-29 | — | — | US | disclosed |
| EP-1816122-A2 | 3,4,5-substituted piperidines as therapeutic compounds | Speedel Experimenta AG (CH) | 2007-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115859-A1 | 3,4,5-SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | REN, AGTR1, AGTR2 | REN 1/4885MAPT 4584/4885THRB 1697/4885 |
| US-20090270380-A1 | 3,4,5-Substituted Piperidines as Renin Inhibitors | REN, AGTR1, AGTR2 | REN 1/4885MAPT 4519/4885THRB 1596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.